Copper Homeostasis in Mammals

哺乳动物的铜稳态

基本信息

  • 批准号:
    8519990
  • 负责人:
  • 金额:
    $ 32.52万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2001
  • 资助国家:
    美国
  • 起止时间:
    2001-02-01 至 2016-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Copper (Cu) plays key catalytic and regulatory functions for biochemical reactions that are critical to normal growth, development and health. Menkes disease and Wilson's disease are two severe human genetic disorders of Cu metabolism that result in childhood mortality and hepatic and neurological dysfunction, respectively. Inappropriate copper balance is linked to myeloneuropathy, prion disease, Alzheimer's and cardiovascular disease and cancer. Consequently, it is critical to understand the mechanisms by which cells control the acquisition, distribution and utilization of Cu. While the identify and functions of the Cu import, intracellular distribution and efflux machinery are beginning to be understood, we know very little about the physiological role of the Ctr2 protein, the regulation of Cu import and how organisms establish global Cu homeostasis. Three specific aims are outlined in this application, which are inter- related by the information they will decipher on the mechanisms of action of the mammalian Cu transport machinery and its regulation at the cellular and systemic level. In the first specific aim the physiological role of the mammalian Ctr2 protein in Cu acquisition will be ascertained through the analysis of mouse Ctr2 knock out mutants, through biochemical and cell biological experiments in cultured cells and through the analysis of Ctr2 mutant proteins. In the second specific aim the regulation of the Ctr1 Cu importer and the Ctr2 protein will be deciphered through an analysis of their post- translational regulation in cell culture. In the third specific aim experiments are outlined to identify a novel blood-borne signal that allows inter-organ communication between peripheral organs such as the heart and the copper acquisition and storage organs. Taken together, these investigations will decipher key functional roles and cellular and systemic regulatory mechanisms for the Cu acquisition machinery, the function of which is essential for normal growth, development and human health.
描述(由申请人提供):铜(CU)扮演着对正常生长,发育和健康至关重要的生化反应的关键催化和调节功能。 Menkes病和威尔逊氏病是CU代谢的两种严重的人类遗传疾病,分别导致儿童死亡率以及肝和神经功能障碍。不适当的铜平衡与骨髓病,prion病,阿尔茨海默氏病和心血管疾病和癌症有关。因此,了解细胞控制CU的获取,分布和利用的机制至关重要。尽管CU进口的识别和功能,但细胞内分布和外排机械开始被理解,但我们对CTR2蛋白的生理作用知之甚少,CU进口的调节以及生物体如何建立全球CU稳态。在本应用中概述了三个具体目标,这些目标与他们将根据哺乳动物Cu运输机制的作用机理的信息相互关联,及其在细胞和系统水平上的调节。在第一个特定目标中,将通过分析小鼠CTR2敲除突变体,通过生化和细胞生物学实验在培养的细胞中和CTR2突变蛋白的分析来确定哺乳动物CTR2蛋白在CU获得中的生理作用。在第二个特定目的中,CTR1 Cu进口商的调节和CTR2蛋白将通过分析其在细胞培养中的转化后调节来解密。在第三个特定的目标实验中,概述了一个新型的血液传播信号,该信号允许外围器官(例如心脏,铜,储存器官和储存器官)之间的孔间通信。综上所述,这些研究将破译关键功能作用以及CU采集机制的细胞和全身调节机制,其功能对于正常生长,发育和人类健康至关重要。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Dennis J Thiele其他文献

Dennis J Thiele的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Dennis J Thiele', 18)}}的其他基金

2015 Cell Biology of Metals Gordon Research Conference
2015金属细胞生物学戈登研究会议
  • 批准号:
    8974528
  • 财政年份:
    2015
  • 资助金额:
    $ 32.52万
  • 项目类别:
Mechanism for copper-deficiency mediated neutropenia
缺铜介导的中性粒细胞减少症的机制
  • 批准号:
    8605173
  • 财政年份:
    2013
  • 资助金额:
    $ 32.52万
  • 项目类别:
Mechanism for copper-deficiency mediated neutropenia
缺铜介导的中性粒细胞减少症的机制
  • 批准号:
    8504553
  • 财政年份:
    2013
  • 资助金额:
    $ 32.52万
  • 项目类别:
HSF1 as a therapeutic target in neurodegenerative disease
HSF1作为神经退行性疾病的治疗靶点
  • 批准号:
    8423028
  • 财政年份:
    2010
  • 资助金额:
    $ 32.52万
  • 项目类别:
HSF1 as a therapeutic target in neurodegenerative disease
HSF1作为神经退行性疾病的治疗靶点
  • 批准号:
    8220871
  • 财政年份:
    2010
  • 资助金额:
    $ 32.52万
  • 项目类别:
HSF1 as a therapeutic target in neurodegenerative disease
HSF1作为神经退行性疾病的治疗靶点
  • 批准号:
    8019461
  • 财政年份:
    2010
  • 资助金额:
    $ 32.52万
  • 项目类别:
HSF1 as a therapeutic target in neurodegenerative disease
HSF1作为神经退行性疾病的治疗靶点
  • 批准号:
    7882166
  • 财政年份:
    2010
  • 资助金额:
    $ 32.52万
  • 项目类别:
FASEB Summer Research Conference "Trace Element Metabolism: Basic and Applied Res
FASEB 夏季研究会议“微量元素代谢:基础与应用研究
  • 批准号:
    7484010
  • 财政年份:
    2008
  • 资助金额:
    $ 32.52万
  • 项目类别:
Copper Homeostasis in Mammals
哺乳动物的铜稳态
  • 批准号:
    9317601
  • 财政年份:
    2001
  • 资助金额:
    $ 32.52万
  • 项目类别:
Copper Homeostasis in Mammals
哺乳动物的铜稳态
  • 批准号:
    8300126
  • 财政年份:
    2001
  • 资助金额:
    $ 32.52万
  • 项目类别:

相似海外基金

Small Molecule Degraders of Tryptophan 2,3-Dioxygenase Enzyme (TDO) as Novel Treatments for Neurodegenerative Disease
色氨酸 2,3-双加氧酶 (TDO) 的小分子降解剂作为神经退行性疾病的新疗法
  • 批准号:
    10752555
  • 财政年份:
    2024
  • 资助金额:
    $ 32.52万
  • 项目类别:
Immunomodulatory ligand B7-1 targets p75 neurotrophin receptor in neurodegeneration
免疫调节配体 B7-1 在神经变性中靶向 p75 神经营养蛋白受体
  • 批准号:
    10660332
  • 财政年份:
    2023
  • 资助金额:
    $ 32.52万
  • 项目类别:
Effect of APP copy number variants in Alzheimer's disease and and Down Syndrome on Reelin expression and function
阿尔茨海默病和唐氏综合症中 APP 拷贝数变异对 Reelin 表达和功能的影响
  • 批准号:
    10760161
  • 财政年份:
    2023
  • 资助金额:
    $ 32.52万
  • 项目类别:
Subtype-Selective Metabotropic Glutamate Receptor PET Ligands
亚型选择性代谢型谷氨酸受体 PET 配体
  • 批准号:
    10576674
  • 财政年份:
    2023
  • 资助金额:
    $ 32.52万
  • 项目类别:
Diagnostic aptamer reagents to develop multi-analyte blood test for pre-clinical, mild and moderate Alzheimer's disease
诊断适体试剂用于开发针对临床前、轻度和中度阿尔茨海默病的多分析物血液检测
  • 批准号:
    10597840
  • 财政年份:
    2023
  • 资助金额:
    $ 32.52万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了